TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02963376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.05 mL/kg based on patient body weight in kilograms (kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.05 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.05 mL/kg is based on patient body weight in kilograms (kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.10 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.10 mL/kg based on patient body weight in kilograms (kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.10 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.10 mL/kg is based on patient body weight in kilograms (kg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.17 mL/kg DDFPe
Description: Prior to injection, DDFPe will be prepared by pharmacy staff. DDFPe will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. DDFPe dosage volume in cc for 0.17 mL/kg based on patient body weight in kilograms (kg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.17 mL/kg Placebo
Description: Prior to injection, the placebo will be prepared by pharmacy staff. The placebo will be administered based on weight at designated doses. Each dose will be prepared on the day of administration and infused directly into the patient using a slow i.v push. The i.v. push shall be 5-10 minutes in duration. The placebo dosage volume in cc for 0.17 mL/kg is based on patient body weight in kilograms (kg).
Study: NCT02506933

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IM
Study: NCT01845363

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin used in antimicrobial prophylaxis
Description: Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.~Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.~The samples were processed by HPLC.
Study: NCT02550340

Intervention type: OTHER
Intervention: acute alcohol intake
Description: Smart phone based ECG recording
Study: NCT01596166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac 0.5 mg/kg (max 30 mg) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide 0.2 mg/kg (max 10 mg) IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metoclopramide
Description: Metoclopramide 0.2 mg/kg (max 10 mg) IV
Study: NCT04738084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meru Health Program
Description: Each week of the 12 week program follows a different theme. Patients and therapists interact asynchronously after their initial Zoom-based intake call. Psychiatrists and medical doctors are available for consults if needed.
Study: NCT04625348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultracore Repose® mattress
Description: residents will be placed on the Ultracore Repose® mattress for the daily care during 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiences and perceptions of healthcare workers
Description: Three focus groups will be set- up at the end of the study to provide insights into how caregivers think about the product and to provide a deeper understanding of the difference between the use of the Ultracore Repose® mattress (versus the Repose overlay mattress® and an alternating air mattress)
Study: NCT02376465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4600 bowel preparation
Description: Oral bowel preparation for colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLI4600 bowel preparation
Description: Oral bowel preparation for colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG based bowel preparation
Description: Oral bowel preparation for colonoscopy
Study: NCT01052649

Intervention type: OTHER
Intervention: Blood sampling
Study: NCT01020760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face down posture
Description: Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
Study: NCT06241586

Intervention type: PROCEDURE
Intervention: The novel PMMI surgical strategy
Description: Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals.

Intervention type: PROCEDURE
Intervention: The novel PMMI surgical strategy
Description: Immediate drainagewas advocated within 24 hours once necrosis was diagnosed. During the treatment course, a hybrid approach was available by flexibly switching interventions. Open surgery was only applied when patients required emergency surgery.~The minimally invasive surgery was selected based on the size, location, and maturity of the necrotic area and stepwise response to intervention. Repeated peritoneal purification was performed until the infected or devitalized tissue was controlled. Patients were subsequently discharged with a drainage catheter and readmitted at 7- to 10-day intervals to receive repeated planned surgery without postoperative irrigation. Patients received a whole-course assessment for individual patients at 7-day predetermined intervals.
Study: NCT04264832

Intervention type: OTHER
Intervention: Clinical data collection
Description: Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life .

Intervention type: OTHER
Intervention: Clinical data collection
Description: Basic characteristics: Participants were carefully characterized with regard to a general health history, a medical history, clinical, demographic and anthropomorphic measurements, skin problems (hirsutism is modified by Ferriman-Gallwey (mF-G) score , global acne score and premature alopecia).~A transvaginal ultrasound scan was performed on every participant during a clinical examination to determine the number of follicles and ovarian volume.~Metabolic and other assessments: General gynecological examination, prolactin, thyroid, androgen, LH, FSH, DA, 5-HT, metabonomics, glucose, insulin, triglyceride (TG), LDL and HDL were determined, OGTT was performed.~Questionnaires: The perceived stress scale(Chinese 14-item PSS), self-rating anxiety scale (SAS）, self-rating depressive scale(SDS) were used to assess the participants' mental health status. The MOS item short from health survey (SF-36) was used to assess the quality of life .
Study: NCT01342237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDCT 1(TTC), HDCT2(MEC)
Description: 1. TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)~2. MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)
Study: NCT04109508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Oral semaglutide current formulation and oral semaglutide new formulation, each in 3 different strengths, administered once daily during 6 treatment periods, each lasting 12 weeks
Study: NCT04592718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow deep breathing plus breath counting
Description: Participants will perform a daily 5-min slow deep breathing exercise for 4 weeks. A breathing rate of 6 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal-paced breathing plus breath counting
Description: Participants will perform a daily 5-min normal-paced breathing exercise for 4 weeks. A breathing rate of 15 breaths per minute will be targeted. In addition, participants will count their breaths during the exercise.
Study: NCT01561196

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial catheterisation
Description: arterial catheterisation in Arterial Radialis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arterial catheterisation
Description: arterial catheterisation in Arterial Radialis
Study: NCT03084380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs
Description: transcatheter arterial chemoembolization + CAR-T infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered at dose of 25mg/m2/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
Study: NCT03769610

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Foley catheter

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient Foley catheter
Study: NCT01816945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOMBA web-based application
Description: Web-based, interactive, social network application.
Study: NCT06241586

Intervention type: PROCEDURE
Intervention: The conventional step-up strategy
Description: Interventions were postponed until 4 weeks after the onset of pancreatitis in line with international guidelines unless the patient showed evidence of progressive clinical deterioration despite the use of maximal supportive care. Patients underwent CT-guided percutaneous catheter drainage as the first step. Treatment response was evaluated after 3 days. If drainage was clinically unsuccessful, a VARD procedure was performed. Similarly, open surgery, which was described by Beger et al., was performed if the VARD procedure failed. Postoperative continuous lavage is performed as a routine procedure.
Study: NCT01984255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV
Description: Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.
Description: Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
Study: NCT03734757

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: imaging in trimodality
Description: PET-CT and MRI
Study: NCT04799041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GTX 2/3
Description: There were 15 patients in this group. Each one received only one treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: There were 15 patients in this group. Each one received only one treatment.
Study: NCT01641120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Intramuscular injection administered using 25 gauge or 30 gauge needle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avonex
Description: Intramuscular injection administered using 25 gauge or 30 gauge needle
Study: NCT03782454

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood samples taken every third hour during the first 48 hours of intensive care
Study: NCT04378283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LET gel (lidocaine 4%, epinephrine 0.1%, and tetracaine 0.5%)
Description: The study is designed to evaluate topical anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA plus infiltration as anesthetic for wound repair.
Description: EMLA plus infiltration as anesthetic for wound repair.
Study: NCT02132104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine application of amnion membrane
Description: Uterine application of amnion membrane following hysteroscopic adhesiolysis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley balloon
Description: Uterine application of Foley balloon

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Foley balloon
Description: Uterine application of Foley balloon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoston
Description: Hormones treatment after surgery.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Femoston
Description: Hormones treatment after surgery.
Study: NCT01178138

Intervention type: DRUG
Group type: OTHER
Intervention: Prazosin
Description: Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
Study: NCT02514967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blisibimod
Description: Administered via subcutaneous injection once per week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via subcutaneous injection once per week
Study: NCT00565994

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
Study: NCT03695913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Diet
Description: Phase I (regular diet):~all participants will eat their normal diet and will log their food.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low carb diet
Description: Phase II (low carb diet):~participants will be asked to eat a low carb diet and log their food

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with no real time feedback
Description: Phase I will collect CGM without real time feedback

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM with real time feedback)
Description: Phase II participants will be asked to scan their sensor at least every eight hours and document their blood sugar before and two hours after eating as well as before breakfast and before going to bed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education material
Description: Phase I: participants will be given the book Always Hungry and be asked to read chapters 1-5 after a health check phone call approximately 5 days after the sensor is placed.~Phase II: participants will be taught about carbohydrates and the benefits and side effects. Additionally, they will be given multiple resources to assist them regarding carbohydrates as well as a book entitled The Calorie King, Calories, Fat, and Carbohydrates. Groceries will also be delivered for 2 recipes that the participants choose from to make.
Study: NCT03980366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: Bilateral Electroconvulsive Therapy (ECT) to treat self-injurious behavior in adults with Autism Spectrum Disorder (ASD).
Study: NCT03729778

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar-13
Description: One time administration of prevnar-13 vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar-13
Description: One time administration of prevnar-13 vaccine
Study: NCT03144648

Intervention type: OTHER
Intervention: lifestyle
Description: Observational study

Intervention type: OTHER
Intervention: lifestyle
Description: Observational study
Study: NCT01601899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 30 mg po BD if wt \< 60kg, or 40 mg po BD if wt \> 60kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stavudine
Description: 20 mg po BD if wt \< 60kg, or 30 mg po BD if wt \> 60kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: 300 mg po QD
Study: NCT01909284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: * BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.~* Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural nerve block
Description: Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural nerve block
Description: Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
Study: NCT00845195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl Nasal Spray, 0.6%
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelastine HCl Nasal Spray, 0.1%
Description: 2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
Study: NCT03575026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-with-movement
Description: Subjects will listen their preferred music and move their body actively with music

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Social activity acts as control with similar dose and intensity with intervention arm
Study: NCT01158339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm 2: CBGT-ISE
Description: Intervention with active performance of the feared movements during group sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1: CBGT
Description: Intervention according to previously mentioned methods.